GCAT

Across TCGA pan-cancer cohorts, GCAT mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GCAT data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GCAT mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GCAT expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where GCAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	All	0.996	0.775	.006	21	view →
HNSC	DFS	Tertile	II,III,IV	1.000	0.878	.029	7	view →
LUAD	DFS	Quartile	III,IV	0.254	0.937	.024	6	view →
GBM	DFS	Tertile	All	0.211	0.468	.024	4	view →
PDAC	DFS	Median	II,III,IV	0.491	0.337	.036	2	view →
UCEC	DFS	Median	All	1.000	0.906	.044	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GCAT–CCRCC (OS)

Open the CCRCC breakdown →